Navigation Links
New technique for developing drugs to treat serious illnesses
Date:11/14/2013

An international team of researchers led by the University of Leicester has "harnessed the power of evolution" to create a new drug for possible use against heart disease, inflammation and other illnesses.

Researchers in the Department of Cardiovascular Sciences and Department of Biochemistry at the University of Leicester, together with colleagues in Cambridge, the USA and Italy, have employed a new technique to create protein-based drugs.

According to Professor Nick Brindle, the lead researcher: "This technique harnesses the power of evolution to engineer specific functions into a protein, such as the ability to neutralise a toxin or to activate healing.

"This involves making a particular cell type generate millions of different variants of our protein, selecting the variants that have improved properties and then repeating the cycle until the protein has been changed to a form with the exact properties we want."

To show how the method works, the group took a protein normally found in the body and evolved it into a form that can block a molecule involved in blood vessel growth and inflammation.

This new protein, called a ligand-trap, is now being developed as a potential therapeutic for treating heart disease, inflammation and other illnesses.

Said Professor Brindle: "The idea that you can evolve proteins into forms that do what you want is not new, but it has been very difficult to do this for many of the complex proteins that we want to use as drugs or for other applications.

"This new approach promises to make engineering of such proteins not only possible but relatively easy. In addition to medicine, these specifically evolved 'designer proteins' have a wide range of applications in the chemical, pharmaceutical, and agricultural industries.

"This is a big step forward. We are hoping that, over the next five years or so, this new protein can be developed into a form that could be
'/>"/>

Contact: Nick Brindle
npjb1@mail.cfs.le.ac.uk
01-162-297-170
University of Leicester
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Novel technique for suturing tissue-engineered collagen graft improves tendon repair
2. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
3. Research reveals bottom feeding techniques of tagged humpback whales in Stellwagen Bank Sanctuary
4. New technique for measuring tree growth cuts down on research time
5. New gene repair technique promises advances in regenerative medicine
6. First child born following embryo screening with new genome analysis technique
7. New palm-sized microarray technique grows 1,200 individual cultures of microbes
8. UMass Amherst researchers develop powerful new technique to study protein function
9. Computer modeling technique goes viral at Brandeis
10. CLEO: 2013 press luncheon spotlights new techniques in optofluidics, temporal cloaking, cryolasers
11. New screening technique paves the way for protein drugs from bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New technique for developing drugs to treat serious illnesses
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Americans to undertake jaunts into the countryside each year could ... a century, according to new research. , Climate change could ... States as summer temperatures linger later into the year, Princeton ... Biogeography . For instance, the paper birch a popular ... could change color one to three weeks later by ...
(Date:9/18/2014)... -- Arizona turned its newborn screening program into a model ... earning it the first-ever Newborn Screening Quality Award from the ... Will Humble, M.P.H., Arizona,s Department of Health Services director, with ... established a policy of full transparency for the length of ... to the lab for analysis, and set a target of ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... has declined steadily in the last three decades. Although ... groups have shown some improvement, according to a recent ... the American Association for Cancer Research. "Our ... treatment, have resulted in profound gains, but these gains ...
... Barbara, Calif.) Scientists at UC Santa Barbara have found ... findings are published online in this week,s issue of the ... species differences in how they use the environment are key ... around us, but the importance of such niches have never ...
... the human brain reshapes itself to store this newfound knowledge. ... does that capacity to adapt reflect our risk for Alzheimer,s ... lives? Dr. Yaniv Assaf of Tel Aviv University,s Department ... effect of memory on brain structure. "With a specific MRI ...
Cached Biology News:Cancer mortality rates experience steady decline 2Scientists demonstrate importance of niche differences in biodiversity 2A window into the brain 2
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... 2011 Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, ... (IND) to conduct a pivotal Phase 3 clinical trial ... nontuberculous mycobacteria (NTM) lung infections has been cleared by ... In 2010, Insmed initially submitted a regulatory filing ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... pivotal trial of pixantrone for the treatment of relapsed/refractory ... now open to patient enrollment. The trial, referred to ... a combination of pixantrone plus rituximab to a combination ...
... Driving value for customers is critical to organizational success across ... customer and an organization, there has to be an integrated ... succeed in the marketplace. Chris Bogan, CEO ... in this month,s special issue of PharmaVoice that the state ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 2Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 3Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 4Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
NNT-1/BSF-3 (N-14)...
Biology Products: